FDA/EMA-supported combination trials exploring alternative targets to CD19 (CD20, CD22, CD30, and the B cell maturation antigen, BCMA) are planned to improve efficacy in the CAR-eligible leukemia/lymphoma patient population (12). This evidence concerns the gene TNFRSF17 and leukemia.